Literature DB >> 8262101

Quantitative changes in platelet counts following major urological pelvic surgery.

I Leibovitch1, J Ben Chaim, G Raviv, Y Mor, I Avigad, B Goldwasser.   

Abstract

Postperative quantitative changes in platelet counts have been reported following various extensive surgical procedures. It is generally accepted that reactive thrombocytosis at levels less than 1,000,000/mm3 is a benign condition and is not associated with increased risk of postoperative thrombohemorrhagic complications. The role of prophylactic treatment with platelet inhibitors in these situations is controversial. We assessed retrospectively the timing and the extent of postoperative thrombocytosis in 85 consecutive patients following major urological pelvic surgery and evaluated its possible clinical significance to hemorrhagic and thromboembolic complications, in view of the coincidence of multiple potential risk factors for thromboembolism in these patients. 73 (85.9%) patients demonstrated marked postoperative changes of platelet counts. In 12 patients (14.1%) we found only minor fluctuations in platelet counts throughout the postoperative period. Two distinct groups of 26 and 47 patients respectively could be identified among these 73 patients, who differed in the rate and extent of changes in platelet counts. Those fluctuations were characterized by an early decrease in platelet levels (mean percentage change of 40 and 60% in groups I and II respectively). This was followed by a gradual increase leading to delayed thrombocytosis (mean percentage change of 225 and 305% in groups I and II respectively). Thromboembolic complications were diagnosed in 5 patients. The occurrence of thromboembolism preceded any significant increase in platelet counts in all 5 patients. There was no correlation between the timing of thromboembolic complications and timing and extent of the change in platelet count. We conclude that reactive thrombocytosis following major urological pelvic surgery is a frequent innocuous finding and is not associated with hemorrhagic or thromboembolic complications.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8262101     DOI: 10.1159/000474327

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  5 in total

1.  Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin.

Authors:  Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo
Journal:  AAPS J       Date:  2015-11-17       Impact factor: 4.009

2.  Role of reactive thrombocytosis after primary cytoreductive surgery in advanced ovarian cancer.

Authors:  Myeong-Seon Kim; Seung Hun Baek; Joseph J Noh; Jung In Shim; Jun Hyeok Kang; Soo Young Jeong; Chel Hun Choi; Tae-Joong Kim; Jeong-Won Lee; Yoo-Young Lee
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

3.  Platelet release of Vascular Endothelial Growth Factor (VEGF) in patients undergoing chemotherapy for breast cancer.

Authors:  Cliona C Kirwan; Gerard J Byrne; Shant Kumar; Garry McDowell
Journal:  J Angiogenes Res       Date:  2009-10-24

4.  Postoperative thrombocytosis: An unusual case report.

Authors:  Garima Baweja Madaan; Zeeba S Jairajpuri; Farooq F Hajini; Sujata Jetley
Journal:  Int J Appl Basic Med Res       Date:  2015 Sep-Dec

5.  Kinetics of mean platelet volume predicts mortality in patients with septic shock.

Authors:  Fanny Vardon-Bounes; Marie-Pierre Gratacap; Samuel Groyer; Stéphanie Ruiz; Bernard Georges; Thierry Seguin; Cédric Garcia; Bernard Payrastre; Jean-Marie Conil; Vincent Minville
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.